CN112424175B - 一种lsd1抑制剂的盐及其晶型 - Google Patents

一种lsd1抑制剂的盐及其晶型 Download PDF

Info

Publication number
CN112424175B
CN112424175B CN201980047189.0A CN201980047189A CN112424175B CN 112424175 B CN112424175 B CN 112424175B CN 201980047189 A CN201980047189 A CN 201980047189A CN 112424175 B CN112424175 B CN 112424175B
Authority
CN
China
Prior art keywords
degrees
compound iii
crystal form
compound
lsd1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980047189.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN112424175A (zh
Inventor
赵乐乐
孙建军
吴凌云
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN112424175A publication Critical patent/CN112424175A/zh
Application granted granted Critical
Publication of CN112424175B publication Critical patent/CN112424175B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980047189.0A 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型 Active CN112424175B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810804068 2018-07-20
CN2018108040683 2018-07-20
PCT/CN2019/096842 WO2020015745A1 (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Publications (2)

Publication Number Publication Date
CN112424175A CN112424175A (zh) 2021-02-26
CN112424175B true CN112424175B (zh) 2022-10-28

Family

ID=69163657

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047189.0A Active CN112424175B (zh) 2018-07-20 2019-07-19 一种lsd1抑制剂的盐及其晶型

Country Status (8)

Country Link
US (1) US12024494B2 (https=)
EP (1) EP3825309B1 (https=)
JP (1) JP7358466B2 (https=)
KR (1) KR102778948B1 (https=)
CN (1) CN112424175B (https=)
AU (1) AU2019303777B2 (https=)
CA (1) CA3106484C (https=)
WO (1) WO2020015745A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228146A1 (zh) * 2020-05-12 2021-11-18 石药集团中奇制药技术（石家庄）有限公司 一种lsd1抑制剂的用途
US20250073232A1 (en) 2021-04-08 2025-03-06 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4522136A1 (en) 2022-05-09 2025-03-19 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
CN116069221A (zh) * 2022-12-27 2023-05-05 北京字跳网络技术有限公司 媒体内容的展示方法、装置、电子设备和存储介质
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675A1 (fr) * 1993-05-27 1994-12-02 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
CN102947265A (zh) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103124724A (zh) * 2010-07-29 2013-05-29 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN103857393A (zh) * 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017195216A1 (en) * 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8993808B2 (en) * 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
MY189367A (en) * 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
TWI833686B (zh) * 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705675A1 (fr) * 1993-05-27 1994-12-02 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
CN102947265A (zh) * 2010-04-19 2013-02-27 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
CN103124724A (zh) * 2010-07-29 2013-05-29 奥瑞泽恩基因组学股份有限公司 Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
CN103857393A (zh) * 2011-03-25 2014-06-11 葛兰素史密斯克莱知识产权（第2号）有限公司 环丙基胺作为lsd1抑制剂
WO2017195216A1 (en) * 2016-05-09 2017-11-16 Jubilant Biosys Limited Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
WO2018137644A1 (zh) * 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
EP3825309A1 (en) 2021-05-26
JP2021530565A (ja) 2021-11-11
AU2019303777A1 (en) 2021-02-11
EP3825309A4 (en) 2022-03-23
CA3106484C (en) 2024-06-25
WO2020015745A1 (zh) 2020-01-23
EP3825309B1 (en) 2023-09-06
CA3106484A1 (en) 2020-01-23
KR102778948B1 (ko) 2025-03-07
JP7358466B2 (ja) 2023-10-10
KR20210034058A (ko) 2021-03-29
AU2019303777B2 (en) 2023-01-19
US12024494B2 (en) 2024-07-02
US20210317096A1 (en) 2021-10-14
CN112424175A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
CN112424175B (zh) 一种lsd1抑制剂的盐及其晶型
CN113784968B (zh) Wee1抑制剂化合物的晶型及其应用
SU1634138A3 (ru) Способ получени производных гуанина или их кислотно-аддитивных фармацевтически приемлемых солей
TW202408510A (zh) Ｃｄｋ抑制劑及其磷酸鹽的多晶型、其製備方法、包含其的醫藥組合物及其用途
WO2018045993A1 (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN115485282B (zh) 一种氧氮杂螺环化合物、其盐型及其晶型
EP4085914A1 (en) Crystal form of pyridopyrimidine derivative and preparation method thereof
EP3915993A1 (en) Crystal form of 1,2,3-triazolo[1,5-a]pyrazines derivative and preparation method for crystal form
JP2024543921A (ja) ＡＸＬキナーゼ阻害剤のモノ－ｐ－トルエンスルホン酸塩およびその結晶形
HK40038512B (en) Salt of lsd1 inhibitor and a polymorph thereof
HK40038512A (en) Salt of lsd1 inhibitor and a polymorph thereof
CN117843638B (zh) 基于rsl3诱导gpx4蛋白降解的双功能分子化合物的制备与应用
RU2794977C2 (ru) Соль ингибитора lsd1 и её полиморфная форма
RU2536685C2 (ru) Фармацевтически приемлемые соли тимодепрессина и способ их получения
CN114728973A (zh) 一种核蛋白抑制剂的晶型及其应用
CN112585120B (zh) 一种血管紧张素ii受体2拮抗剂的盐型、晶型及其制备方法
EP4116300A1 (en) Crystal of tricyclic compound acting on crbn protein and preparation method therefor
TWI703134B (zh) 一種具有抗癌作用的化合物及其製備方法和應用（二）
CN112194653B (zh) 一种嘧啶苯并咪唑杂合物、制备方法及抗结肠癌用途
CN111484497B (zh) 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
EP4089086B1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
JPS5998069A (ja) スパルソマイシン（Ｓｃ−Ｒｓ）誘導体およびそれらを含む医薬組成物
WO2025011618A1 (zh) 噻唑并吡嗪类化合物的盐或其结晶及其应用
CN116685588A (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用
WO2021164789A1 (zh) 一种吡唑并嘧啶类化合物的晶型及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038512

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant